Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. CryptigenTM TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden CryptigenTM TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. The company has an extensive proprietary library of CryptigenTM TSAs that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, the Harrington Discovery Institute and Novateur Ventures. The company has raised over US$13.6 million in seed financing. Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada. Please see www.epitopea.com for more information and follow us on LinkedIn. For more information about our investors please see the following links: Advent Life Sciences: www.adventls.com CTI Life Sciences: https://www.ctisciences.com Cambridge Innovation Capital: www.cic.vc Fonds de solidarité FTQ: https://www.fondsftq.com Novateur Ventures: https://www.novateur.ca Harrington Discovery Institute/University Health Holdings: https://www.harringtondiscovery.org For more information about the Université de Montréal, please see here: https://www.umontreal.ca/en/ For more information about IRICoR, please see here: https://www.iricor.ca SOURCE Epitopea